Gilead Sciences' $4 Million Grant for Viral Hepatitis Elimination in Asia

Gilead Sciences, in collaboration with the World Hepatitis Alliance, awarded a $4 million grant to support innovative projects addressing viral hepatitis in Asia. The grant aims to eliminate viral hepatitis by 2030 through community-led initiatives. Organizations in South Korea, Taiwan, India, Hong Kong, and Vietnam received funding to drive testing, improve linkage to care, and raise awareness about hepatitis B and C. The grant supports local efforts to tackle stigma and discrimination, contributing to the global goal of eliminating viral hepatitis as a public health threat. Through partnerships with community organizations, Gilead is working towards a future where healthcare is accessible to all, and the burden of hepatitis is a thing of the past.